Medtronic’s Profit Falls After Charge for Blood Pressure Device

Medtronic Inc. (MDT), the world’s biggest maker of heart-rhythm devices, said fiscal third-quarter profit fell 23 percent after it took a charge for the 2010 acquisition of Ardian Inc. and its failed high blood pressure treatment.

Net income in the three months ended Jan. 24 fell to $762 million, or 75 cents a share, from $988 million, or 97 cents, a year earlier, the Minneapolis-based company said in a statement. Profit of 91 cents a share, excluding one-time items such as the write-off of Ardian assets, matched the average of 18 analyst estimates compiled by Bloomberg.

The company narrowed its earnings forecast for fiscal 2014 to $3.81 to $3.83 a share, from $3.80 to $3.85 a share.

Medtronic rose less than 1 percent to $56.88 Friday in New York trading. The shares have risen 21 percent in the past 12 months.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.